Celldex teams up with Roche for immunotherapy combo trial; Imbruvica comes through in another CLL trial;

@FierceBiotech: ICYMI yesterday: Department reorganizations at Biogen Idec raise fears of future cuts. Report | Follow @FierceBiotech

@JohnCFierce: $KITE sees its TCR work as a key distinguishing factor in an increasingly crowded field. Sets up Kite EU in $21M deal. Release | Follow @JohnCFierce

> Celldex ($CLDX) signed a deal to test how well varlilumab, its cancer-treating antibody, can work in tandem with Roche's ($RHHBY) high-profile PD-L1 therapy MPDL3280A. The two plan to launch a Phase I/II study in kidney cancer later this year. More

> Imbruvica, a cancer drug invented by AbbVie ($ABBV) takeout target Pharmacyclics ($PCYC), notched more positive clinical results in a trial on a particularly deadly blood cancer, bolstering both companies' hopes that it can continue to grow on the balance sheet. Item

> Applied Molecular Transport, one of the latest companies to take part in Johnson & Johnson's ($JNJ) JLABS program, has a novel approach to creating oral biologic therapies. News

Medical Device News

@FierceMedDev: Illumina hits U.K. company with prenatal test patent suit. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: J&J hosts oral biologics startup at its new incubator to help it find Remicade's replacement. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: FDA warning on power morcellators triggers "broad transformation" in clinical practice. WSJ story (sub. req.) | Follow @EmilyWFierce

> Fast-spreading CRISPR tech inspires new preclinical work on blood cancers. Story

> Physicians opt out of morcellator procedures months after FDA warning. Report

> Medtronic backs diabetes device connectivity, analysis startup Glooko in $16.5M Series B. Article

Pharma News

@FiercePharma: ICYMI yesterday: All clear for Actavis to become Allergan as EU watchdogs approve $66B merger. Article | Follow @FiercePharma

@EricPFierce: DEA says it is not the cause of shortages of scheduled drugs, that it is just misunderstood. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> Hep C meds cost-effective, but affordable? With new 46% discounts, maybe. Article

> Endo's shown it's willing to spend. But with Salix gone, what's left worth buying? More

> Imbruvica cocktail stalls CLL in new trial, raising hopes for bigger market. Report

Drug Delivery News

> Efforts at intracochlear drug delivery to treat hearing loss gaining momentum. Item

> Depomed picks up loan for second half of $1.05B Nucynta acquisition from J&J. More

> New optogenetics technique does away with genetic modification. Story

> Glide touts studies of its delivery system as it prepares to take on Novartis' Sandostatin. Item

> J&J hosts oral biologics startup at its new incubator to help it find Remicade's replacement. Article

Pharma Manufacturing News

> Malaysia's CCM Duopharma Biotech adds plants to compete better. More

> Actavis becomes Allergan and looks to manufacturing for cutting costs. Item

> WuXi to bulk up cell therapy manufacturing in Philadelphia. Article

> New York set to get another drug manufacturing project. Story

> Florida CDMO gets taxpayer boost for expansion, 100 jobs. Report

Pharma Asia News

> Astellas says stem cell research promising on kidney failure. Item

> India and U.S. scientists battle over virulence of swine flu strain in India. Report

> Big Three Asia pharma markets poised to soar in 2015, reports say. Story

> South Korea's Green Cross pushes into cell therapy manufacturing in China. More

> Doctor outreach at heart of Daiichi Sankyo $39 million Medicaid lawsuit settlement. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.